235 related articles for article (PubMed ID: 25907231)
1. Cessation of Primary Androgen Deprivation Therapy for Men With Localized Prostate Cancer.
Fujimoto N; Kubo T; Tomisaki I
Clin Genitourin Cancer; 2015 Aug; 13(4):359-363. PubMed ID: 25907231
[TBL] [Abstract][Full Text] [Related]
2. Interpreting Testosterone and Concomitant Prostate Specific Antigen Values during Androgen Deprivation Therapy for Recurrent Prostate Cancer.
Tremblay S; Summers-Trasiewicz L; Pouliot F; Crook JM; Ding K; Klotz L; Toren P
J Urol; 2021 Nov; 206(5):1166-1176. PubMed ID: 34184929
[TBL] [Abstract][Full Text] [Related]
3. Significance of prostate-specific antigen kinetics after three-dimensional conformal radiotherapy with androgen deprivation therapy in patients with localized prostate cancer.
Fukuokaya W; Kim S; Natsuyama T; Matsuzaki K; Shiomi H; Kitoh H; Utsumi N; Kurosaki H; Inoue M; Akakura K
Int J Clin Oncol; 2018 Apr; 23(2):361-367. PubMed ID: 29151227
[TBL] [Abstract][Full Text] [Related]
4. Immediate versus deferred initiation of androgen deprivation therapy in prostate cancer patients with PSA-only relapse. An observational follow-up study.
Garcia-Albeniz X; Chan JM; Paciorek A; Logan RW; Kenfield SA; Cooperberg MR; Carroll PR; Hernán MA
Eur J Cancer; 2015 May; 51(7):817-24. PubMed ID: 25794605
[TBL] [Abstract][Full Text] [Related]
5. Abiraterone acetate plus prednisone in non-metastatic biochemically recurrent castration-naïve prostate cancer.
Spetsieris N; Boukovala M; Alafis I; Davis J; Zurita A; Wang X; Tu SM; Chapin BF; Aparicio A; Corn P; Wang J; Subudhi SK; Araujo J; Papadopoulos J; Pruitt L; Weldon JA; Logothetis CJ; Efstathiou E
Eur J Cancer; 2021 Nov; 157():259-267. PubMed ID: 34536949
[TBL] [Abstract][Full Text] [Related]
6. Combination of Androgen Deprivation Therapy and Salvage Radiotherapy versus Salvage Radiotherapy Alone for Recurrent Prostate Cancer after Radical Prostatectomy.
Yoo S; You D; Kim YS; Hong JH; Ahn H; Kim CS
Urol Int; 2017; 99(4):406-413. PubMed ID: 29020683
[TBL] [Abstract][Full Text] [Related]
7. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
8. Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone-Sensitive Prostate Cancer Treated With Androgen Deprivation With or Without Docetaxel.
Harshman LC; Chen YH; Liu G; Carducci MA; Jarrard D; Dreicer R; Hahn N; Garcia JA; Hussain M; Shevrin D; Eisenberger M; Kohli M; Plimack ER; Cooney M; Vogelzang NJ; Picus J; Dipaola R; Sweeney CJ;
J Clin Oncol; 2018 Feb; 36(4):376-382. PubMed ID: 29261442
[TBL] [Abstract][Full Text] [Related]
9. Cessation of long-term adjuvant androgen deprivation therapy after radical prostatectomy: is it feasible?
Taguchi S; Fukuhara H; Morikawa T; Matsumoto A; Miyazaki H; Nakagawa T; Fujimura T; Kume H; Igawa Y; Homma Y
Jpn J Clin Oncol; 2016 Dec; 46(12):1143-1147. PubMed ID: 27620729
[TBL] [Abstract][Full Text] [Related]
10. High PSA anxiety and low health literacy skills: drivers of early use of salvage ADT among men with biochemically recurrent prostate cancer after radiotherapy?
Mahal BA; Chen MH; Bennett CL; Kattan MW; Sartor O; Stein K; D'Amico AV; Nguyen PL
Ann Oncol; 2015 Jul; 26(7):1390-5. PubMed ID: 25926039
[TBL] [Abstract][Full Text] [Related]
11. Optimal PSA Threshold for Androgen-Deprivation Therapy in Patients with Prostate Cancer following Radical Prostatectomy and Adjuvant Radiation Therapy.
Ahn HK; Lee KS; Kim D; Rha KH; Hong SJ; Chung BH; Koo KC
Yonsei Med J; 2020 Aug; 61(8):652-659. PubMed ID: 32734728
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant hormonal therapy in prostate cancer - impact of PSA level before radiotherapy.
Dolezel M; Odrazka K; Vanasek J; Vaculikova M; Vlkova-Sefrova J; Jansa J; Macingova Z; Brodak M; Hartmann I; Melichar B
J BUON; 2013; 18(4):949-53. PubMed ID: 24344022
[TBL] [Abstract][Full Text] [Related]
13. Low testosterone at first prostate-specific antigen failure and assessment of risk of death in men with unfavorable-risk prostate cancer treated on prospective clinical trials.
Atkins KM; Chen MH; Wu J; Renshaw AA; Loffredo M; Kantoff PW; Small EJ; D'Amico AV
Cancer; 2018 Apr; 124(7):1383-1390. PubMed ID: 29266181
[TBL] [Abstract][Full Text] [Related]
14. Docetaxel, bevacizumab, and androgen deprivation therapy for biochemical disease recurrence after definitive local therapy for prostate cancer.
McKay RR; Gray KP; Hayes JH; Bubley GJ; Rosenberg JE; Hussain A; Kantoff PW; Taplin ME
Cancer; 2015 Aug; 121(15):2603-11. PubMed ID: 25903013
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.
Fizazi K; Faivre L; Lesaunier F; Delva R; Gravis G; Rolland F; Priou F; Ferrero JM; Houede N; Mourey L; Theodore C; Krakowski I; Berdah JF; Baciuchka M; Laguerre B; Fléchon A; Ravaud A; Cojean-Zelek I; Oudard S; Labourey JL; Chinet-Charrot P; Legouffe E; Lagrange JL; Linassier C; Deplanque G; Beuzeboc P; Davin JL; Martin AL; Habibian M; Laplanche A; Culine S
Lancet Oncol; 2015 Jul; 16(7):787-94. PubMed ID: 26028518
[TBL] [Abstract][Full Text] [Related]
16. Association between immunosuppressive cytokines and PSA progression in biochemically recurrent prostate cancer treated with intermittent hormonal therapy.
Hawley JE; Pan S; Figg WD; Lopez-Bujanda ZA; Strope JD; Aggen DH; Dallos MC; Lim EA; Stein MN; Hu J; Drake CG
Prostate; 2020 Mar; 80(4):336-344. PubMed ID: 31899823
[TBL] [Abstract][Full Text] [Related]
17. Timing of Androgen Deprivation Treatment for Men with Biochemical Recurrent Prostate Cancer in the Context of Novel Therapies.
Marshall CH; Chen Y; Kuo C; Cullen J; Jiang J; Rosner I; Markowski M; McLeod DG; Trock BJ; Eisenberger MA
J Urol; 2021 Sep; 206(3):623-629. PubMed ID: 34003011
[TBL] [Abstract][Full Text] [Related]
18. Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treated with androgen-deprivation therapy.
Choueiri TK; Xie W; D'Amico AV; Ross RW; Hu JC; Pomerantz M; Regan MM; Taplin ME; Kantoff PW; Sartor O; Oh WK
Cancer; 2009 Mar; 115(5):981-7. PubMed ID: 19152438
[TBL] [Abstract][Full Text] [Related]
19. Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer.
Planas J; Celma A; Placer J; Cuadras M; Regis L; Gasanz C; Trilla E; Salvador C; Lorente D; Morote J
Scand J Urol; 2016 Dec; 50(6):425-428. PubMed ID: 27628623
[TBL] [Abstract][Full Text] [Related]
20. Intermittent androgen deprivation in prostate cancer patients: factors predictive of prolonged time off therapy.
Strum SB; Scholz MC; McDermed JE
Oncologist; 2000; 5(1):45-52. PubMed ID: 10706649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]